Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial (2021)

First Author: Humby Frances

Attributed to: Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue responses to stratify medicines. funded by MRC

No abstract provided

Type: Journal Article/Review

Volume: 397

Parent Publication: LANCET

Issue: 10271